Antengene Announces Submission to the Human Research Ethics Committee in Australia for a Phase I Trial of ATG-018 ...Middle East

Developed in-house by internal R&D Team at Antengene, ATG-018 is an orally-available, small molecule ATR inhibitor that targets DNA Damage Response (DDR) pathways. The Phase I study will evaluate the safety, pharmacology and preliminary efficacy of ATG-018 in patients with advanced solid...

Hence then, the article about antengene announces submission to the human research ethics committee in australia for a phase i trial of atg 018 was published today ( Wednesday 27/04/2022 - 03:50 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Antengene Announces Submission to the Human Research Ethics Committee in Australia for a Phase I Trial of ATG-018 )

Also on site :

• 2000s Heavy Metal Band Shares Exciting Music Festival News
• Saudi to Sudan: Can Pakistan expand military footprint across Arab world?
• Iconic '80s Heavy Metal Band Announces 2026 North America Tour Dates